Login to your account

Cancer remains a significant disease and leading cause of death, and there is a need for more sophisticated and effective therapies. Personalized treatments for cancer show great promise in curing the disease, and developing novel personalized therapy approaches is one of our main goals. Our selected platform to treat cancer is oncolytic virus. These viruses have been engineered to selectively infect and kill cancer cells in a process called, “oncolysis.” During infection by oncolytic viruses, the immune system is switched on, eliciting a virus-specific immune response. The same infection can also elicits a tumor-specific immune response that, in some cases, synergizes with the virus and provides a long-lasting beneficial effect for patients. Our group explores mechanisms to understand and ultimately to control the virus-host interface and to revert the anti-viral response into an anti-tumoral response. To facilitate these studies, we have developed innovative and sophisticated techniques that allow us to continually and rapidly monitor tumor antigen presentation. This information can then be used to generate tumor-specific (or patient-specific) oncolytic vaccines. Using similar viral technology, we are also researching and developing potential vaccines for malaria, influenza, and other infectious diseases.